Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| CDXS - Codexis | 8.92% | Hold | 1,345,000 | $31.27 | $42M | — | — |
| OCUL - Ocular Therapeutix | 8.83% | Reduce −7.8% | 5,974,800 | $6.97 | $42M | −505,200 | −$23M |
| Chimerix | 7.61% | Add +10.9% | 5,580,000 | $6.43 | $36M | +550,000 | +$5M |
| CLDX - Celldex Therapeutics | 6.92% | Reduce −14.3% | 844,000 | $38.64 | $33M | −141,000 | −$20M |
| HROW - Harrow Health | 6.02% | Hold | 3,285,000 | $8.64 | $28M | — | — |
| CYTK - Cytokinetics | 5.61% | Hold | 580,000 | $45.58 | $26M | — | — |
| CRNX - Crinetics Pharmaceuticals | 4.36% | Add +80.1% | 724,400 | $28.41 | $21M | +322,287 | +$12M |
| Protara Therapeutics | 3.82% | Add +3.6% | 2,650,000 | $6.79 | $18M | +91,528 | +$291K |
| Semler Scientific | 3.34% | Reduce −23.7% | 172,000 | $91.65 | $16M | −53,566 | −$12M |
| STXS - Stereotaxis | 3.32% | Hold | 2,526,500 | $6.20 | $16M | — | — |
| Keros Therapeutics | 3.30% | Reduce −24.6% | 265,750 | $58.51 | $16M | −86,750 | +$2M |
| Kiniksa Pharmaceuticals · CL A | 2.56% | Reduce −21.8% | 1,025,000 | $11.77 | $12M | −285,000 | −$3M |
| PTGX - Protagonist Therapeutics | 2.48% | Add +3.6% | 342,000 | $34.20 | $12M | +11,778 | +$6M |
| PRQR - Proqr Therapeutics | 2.44% | Add +0.8% | 1,435,510 | $8.01 | $11M | +11,310 | −$423K |
| ETON - Eton Pharmaceuticals | 2.17% | Reduce −22.8% | 2,385,000 | $4.29 | $10M | −703,100 | −$5M |
| Sutro Biopharma | 2.15% | Add +26.4% | 680,000 | $14.88 | $10M | +142,200 | −$41K |
| Merus | 2.14% | Add +217.0% | 317,800 | $31.80 | $10M | +217,550 | +$8M |
| LRMR - Larimar Therapeutics | 2.02% | Add +6.1% | 883,602 | $10.79 | $10M | +50,795 | −$68K |
| Fortress Biotech | 1.99% | Hold | 3,750,000 | $2.50 | $9M | — | — |
| Reata Pharmaceuticals · CLASS A | 1.85% | New | 330,000 | $26.37 | $9M | +330,000 | +$9M |
| Tracon Pharmaceuticals | 1.79% | Add +21.3% | 3,055,000 | $2.77 | $8M | +536,629 | −$1M |
| Ginkgo Bioworks · CLASS A | 1.64% | New | 929,780 | $8.31 | $8M | +929,780 | +$8M |
| PCVX - Vaxcyte | 1.59% | Reduce −10.6% | 315,800 | $23.79 | $8M | −37,600 | −$1M |
| Macrogenics | 1.57% | Hold | 462,000 | $16.05 | $7M | — | — |
| XOMA - XOMA Del | 1.50% | Hold | 338,350 | $20.85 | $7M | — | — |
| TELA - Tela Bio | 1.22% | Add +1.5% | 449,867 | $12.80 | $6M | +6,668 | −$296K |
| Hyperfine · CL A | 1.17% | New | 763,075 | $7.24 | $6M | +763,075 | +$6M |
| BBIO - Bridgebio Pharma | 1.16% | Reduce −35.9% | 328,100 | $16.68 | $5M | −183,400 | −$19M |
| Neoleukin Therapeutics | 1.07% | Hold | 1,047,300 | $4.82 | $5M | — | — |
| FDMT - 4D Molecular Therapeutics | 1.07% | New | 229,000 | $21.94 | $5M | +229,000 | +$5M |
| Verastem | 1.01% | Hold | 2,325,000 | $2.05 | $5M | — | — |
| Sierra Oncology | 0.76% | Hold | 165,778 | $21.74 | $4M | — | — |
| Mei Pharma | 0.74% | Reduce −16.0% | 1,315,000 | $2.67 | $4M | −250,000 | −$808K |
| Nucana | 0.60% | Add +147.9% | 1,189,000 | $2.38 | $3M | +709,400 | +$2M |
| Avalo Therapeutics | 0.53% | Hold | 1,459,400 | $1.70 | $2M | — | — |
| Synlogic | 0.44% | New | 850,000 | $2.42 | $2M | +850,000 | +$2M |
| Aveo Biosciences | 0.26% | Reduce −42.2% | 263,400 | $4.69 | $1M | −192,200 | −$2M |
| LQDA - Liquidia | 0.02% | New | 16,800 | $4.88 | $82K | +16,800 | +$82K |
| Biolinerx | 0.01% | Hold | 16,667 | $2.04 | $34K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2021 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Adamas Pharmaceuticals | 1.34% | Exit | 0 | $4.91 | $7M | −1,460,000 | −$7M |
| Holding | 1.30% | Exit | 0 | $33.98 | $7M | −205,381 | −$7M |
| Acutus Medical | 0.97% | Exit | 0 | $8.84 | $5M | −590,000 | −$5M |
| Optinose | 0.87% | Exit | 0 | $3.00 | $5M | −1,558,500 | −$5M |
| Forma Therapeutics | 0.79% | Exit | 0 | $23.19 | $4M | −182,950 | −$4M |
| FOLD - Amicus | 0.57% | Exit | 0 | $9.55 | $3M | −320,800 | −$3M |
| Viracta Therapeutics | 0.39% | Exit | 0 | $8.02 | $2M | −258,556 | −$2M |
| Sio Gene Therapies | 0.39% | Exit | 0 | $2.17 | $2M | −955,000 | −$2M |
| Leap Therapeutics | 0.36% | Exit | 0 | $4.01 | $2M | −476,000 | −$2M |
| Precision Biosciences | 0.35% | Exit | 0 | $11.54 | $2M | −163,900 | −$2M |
| WHWK - Aadi Biosciences | 0.25% | Exit | 0 | $29.36 | $1M | −45,020 | −$1M |
| Aptose Biosciences | 0.22% | Exit | 0 | $2.18 | $1M | −549,000 | −$1M |
| AKBA - Akebia Therapeutics | 0.17% | Exit | 0 | $2.88 | $897K | −311,300 | −$897K |
| Selecta Biosciences | 0.08% | Exit | 0 | $4.16 | $441K | −106,000 | −$441K |
| Cymabay Therapeutics | 0.08% | Exit | 0 | $3.65 | $420K | −115,015 | −$420K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2